Veradigm (STU:AL21) Beneish M-Score: 0.00 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AL21 Veradigm Inc STU:AL21
17 GF Score
Price €3.40
View Full Analysis

What is Veradigm Beneish M-Score?

Veradigm STU:AL21 17 Beneish M-Score is 0.00 as of Jul. 14, 2026. GuruFocus rates STU:AL21 with a GF Score™ of 17/100. Among 630 Healthcare Providers & Services companies, Veradigm ranks worse than 158730% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Veradigm's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Veradigm was 0.00. The lowest was 0.00. And the median was 0.00.


Veradigm Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Veradigm's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Veradigm Beneish M-Score Chart

Veradigm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.63 -1.16 -2.24 0.00 0.00

Veradigm Semi-Annual Data
Dec03 Dec04 Dec05 Dec06 Dec07 May09 May10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.63 -1.16 -2.24 0.00 0.00

STU:AL21 vs CTEV, EVH, PHR: Beneish M-Score Comparison

For the Health Information Services subindustry, Veradigm's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veradigm Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Veradigm's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Veradigm's Beneish M-Score falls into.


STU:AL21
17GF Score
Veradigm Inc STU:AL21
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veradigm Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Veradigm for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9334+0.528 * 0.9326+0.404 * 0.7592+0.892 * 1.0862+0.115 * 0.7923
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4867+4.679 * -0.105787-0.327 * 0.7958
=-3.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Total Receivables was €165.9 Mil.
Revenue was €555.1 Mil.
Gross Profit was €291.1 Mil.
Total Current Assets was €641.6 Mil.
Total Assets was €1,420.5 Mil.
Property, Plant and Equipment(Net PPE) was €20.2 Mil.
Depreciation, Depletion and Amortization(DDA) was €109.4 Mil.
Selling, General, & Admin. Expense(SGA) was €159.7 Mil.
Total Current Liabilities was €217.4 Mil.
Long-Term Debt & Capital Lease Obligation was €200.9 Mil.
Net Income was €-81.6 Mil.
Gross Profit was €-40.4 Mil.
Cash Flow from Operations was €109.1 Mil.
Total Receivables was €163.6 Mil.
Revenue was €511.0 Mil.
Gross Profit was €250.0 Mil.
Total Current Assets was €574.6 Mil.
Total Assets was €2,045.3 Mil.
Property, Plant and Equipment(Net PPE) was €31.9 Mil.
Depreciation, Depletion and Amortization(DDA) was €64.4 Mil.
Selling, General, & Admin. Expense(SGA) was €98.9 Mil.
Total Current Liabilities was €432.3 Mil.
Long-Term Debt & Capital Lease Obligation was €324.6 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(165.877 / 555.088) / (163.602 / 511.023)
=0.29883 / 0.320146
=0.9334

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(249.965 / 511.023) / (291.148 / 555.088)
=0.489146 / 0.524508
=0.9326

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (641.588 + 20.238) / 1420.458) / (1 - (574.554 + 31.912) / 2045.257)
=0.534076 / 0.703477
=0.7592

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=555.088 / 511.023
=1.0862

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(64.406 / (64.406 + 31.912)) / (109.429 / (109.429 + 20.238))
=0.668681 / 0.843923
=0.7923

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(159.726 / 555.088) / (98.908 / 511.023)
=0.287749 / 0.193549
=1.4867

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((200.916 + 217.415) / 1420.458) / ((324.632 + 432.255) / 2045.257)
=0.294504 / 0.370069
=0.7958

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-81.62 - -40.445 - 109.091) / 1420.458
=-0.105787

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Veradigm has a M-score of -3.13 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Veradigm (STU:AL21) has a Beneish M-Score of 0.00 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Veradigm and its competitors. According to the industry distribution chart, Veradigm ranks #999999 out of 630 companies in the Healthcare Providers & Services industry.
Is Veradigm's Beneish M-Score too high?
Veradigm's current Beneish M-Score is 0.00. Based on the distribution chart, Veradigm ranks #999999 out of 630 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Veradigm has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Veradigm's Beneish M-Score compare to CTEV and EVH?
According to the Healthcare Providers & Services industry distribution chart, Veradigm ranks #999999 out of 630 companies for Beneish M-Score. This places Veradigm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Veradigm and its competitors. Veradigm's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veradigm stock overvalued right now?
Veradigm (STU:AL21) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Veradigm's overall GF Score™ is 17/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Veradigm (STU:AL21), the current Beneish M-Score is 0.00 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veradigm Business Description

Other Exchanges MDRX:USA
Address 222 Merchandise Mart Plaza, Suite 2024, Chicago, IL, USA, 60654
Veradigm Inc together with its subsidiaries, is a healthcare software-as-a-service (SaaS) technology, data and analytics company spanning the three pillars of healthcare: Provider, Payer and Life Science. Its Provider segment represents the source of revenue, followed by the Payer segment, with the Life Science segment contributing a comparatively smaller portion. Its portfolio addresses a range of healthcare industry needs, with the goal of transforming health insightfully, providing key healthcare stakeholders with data, insights and artificial intelligence (AI) enhanced solutions to help improve health outcomes and reduce costs.
17GF Score

Get the complete analysis for STU:AL21

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price